Goldman Sachs Group Inc Stoke Therapeutics, Inc. Transaction History
Goldman Sachs Group Inc
- $706 Billion
- Q2 2025
A detailed history of Goldman Sachs Group Inc transactions in Stoke Therapeutics, Inc. stock. As of the latest transaction made, Goldman Sachs Group Inc holds 1,301,381 shares of STOK stock, worth $46.3 Million. This represents 0.0% of its overall portfolio holdings.
Number of Shares
1,301,381
Previous 1,662,039
21.7%
Holding current value
$46.3 Million
Previous $11.1 Million
33.64%
% of portfolio
0.0%
Previous 0.0%
Shares
22 transactions
Others Institutions Holding STOK
# of Institutions
138Shares Held
58MCall Options Held
2.7KPut Options Held
57.4K-
Black Rock Inc. New York, NY5.41MShares$193 Million0.0% of portfolio
-
Lynx1 Capital Management LP San Juan, PR5.4MShares$192 Million18.16% of portfolio
-
Rtw Investments, LP New York, NY5.12MShares$182 Million0.89% of portfolio
-
Baker Bros. Advisors LP New York, NY4.63MShares$165 Million0.53% of portfolio
-
Redmile Group, LLC San Francisco, CA4.38MShares$156 Million6.04% of portfolio
About Stoke Therapeutics, Inc.
- Ticker STOK
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 39,419,300
- Market Cap $1.4B
- Description
- Stoke Therapeutics, Inc., an early-stage biopharmaceutical company, develops novel antisense oligonucleotide (ASO) medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary Targeted Augmentation of Nuclear Gene Output to design ASOs to precisely upregulate protein expression. I...